ArticleEuropean respiratory review : an official journal of the European Respiratory Society2023
New trends in pulmonary hypertension.
Article in European respiratory review : an official journal of the European Respiratory Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Advances in Novel Therapeutic Strategies for Pulmonary Arterial Hypertension.Canadian respiratory journal · 2026Review
- Pulmonary arterial diameter remains dilated despite a reduction of pulmonary arterial pressure post lung transplantation: a retrospective study.Quantitative imaging in medicine and surgery · 2025Article
- Atrial septostomy in the management of pulmonary arterial hypertension: past, present, and future.European journal of medical research · 2025Review
- Location of Terminal Care in Pulmonary Hypertension.CJC open · 2025Article
- Mechanistic insights into the role of EGLN3 in pulmonary vascular remodeling and endothelial dysfunction.Respiratory research · 2025Review
- A swine model of severe chronic thromboembolic pulmonary hypertension induced by repeated pulmonary artery long suture injection.Frontiers in cardiovascular medicine · 2025Article
- Analysis of clinical characteristics of patients with pulmonary hypertension in Chaya County, Chamdo, Tibet.Cardiovascular diagnosis and therapy · 2024Article
- microRNA-based electrochemical biosensor for early detection of pulmonary arterial hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Sarcoidosis Associated Pulmonary Hypertension.Biomedicines · 2024Review
- ERS International Congress 2023: highlights from the Pulmonary Vascular Diseases Assembly.ERJ open research · 2024Article
- Exploring the Multifaceted Potential of Sildenafil in Medicine.Medicina (Kaunas, Lithuania) · 2023Review
- Pharmacology and Rationale for Seralutinib in the Treatment of Pulmonary Arterial Hypertension.International journal of molecular sciences · 2023Review
- The flare of care for rare: per aspera ad astra for rare lung diseases!European respiratory review : an official journal of the European Respiratory Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension (PH) is a prevalent disease of the pulmonary vasculature that is characterised by considerable morbidity and mortality. Substantial efforts have been made in recent years to improve disease recognition, diagnosis and management, and this is reflected in current guidelines. The haemodynamic definition of PH has been revised and a definition for exercise PH has been provided. Risk stratification has been refined and the importance of comorbidities and phenotyping have been highlighted. These changes provide an opportunity to potentially identify pulmonary vascular disease at an earlier stage and to enhance patient-centred, goal-orientated treatment decisions. A promising fourth treatment pathway for pulmonary arterial hypertension and potential targeted therapies for group 3 PH are on the horizon, concepts which seemed inconceivable only a few years ago. Beyond medication, there is a greater appreciation for the importance of supervised training in stable PH and the possible role of interventional therapies in select cases. The landscape of PH is changing and it is characterised by progress, innovation and opportunities. In this article, we highlight some of the new trends in PH, with a specific focus on the revised European Society of Cardiology/European Respiratory Society 2022 guidelines for the diagnosis and management of PH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.